Michael Gelband’s Aclaris Therapeutics ACRS Stock Holding History

Michael Gelband’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-16,895	Closed	-$63.4K	–	1519
2026 Q1	$63.4K	Buy	+16,895	New	+$57K	﹤0.01%	1455
2025 Q2	–	Sell	-59,865	Closed	-$92K	–	1417
2025 Q1	$92K	Buy	59,865 +49,228	+463%	+$105K	﹤0.01%	1349
2024 Q4	$26K	Buy	+10,637	New	+$26.5K	﹤0.01%	1433
2023 Q4	–	Sell	-146,454	Closed	-$1M	–	1406
2023 Q3	$1M	Buy	+146,454	New	+$1.25M	0.01%	969
2023 Q1	–	Sell	-14,753	Closed	-$232K	–	1704
2022 Q4	$232K	Buy	+14,753	New	+$237K	﹤0.01%	1421
2021 Q3	–	Sell	-28,975	Closed	-$509K	–	2036
2021 Q2	$509K	Sell	28,975 -111,880	-79%	-$2.54M	0.01%	1385
2021 Q1	$3.55M	Sell	140,855 -81,793	-37%	-$1.6M	0.05%	377
2020 Q4	$1.44M	Buy	+222,648	New	+$939K	0.01%	684

Other funds holding ACRS

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

Michael Gelband's ACRS Position: Q2 2026 in Review

Michael Gelband sold out of Aclaris Therapeutics (ACRS) in Q2 2026, closing a stake of 16,895 shares — an estimated $63.4K sold.

Michael Gelband first reported a position in ACRS in Q4 2020 and held it in 8 quarters. The position peaked at $3.55M in Q1 2021. 148 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

Michael Gelband reported no remaining Aclaris Therapeutics position as of Q2 2026 after selling out during the quarter.
Michael Gelband sold 16,895 Aclaris Therapeutics shares in Q2 2026, an estimated $63.4K.
Michael Gelband first reported a position in Aclaris Therapeutics in Q4 2020 and held it in 8 quarters.
Michael Gelband's Aclaris Therapeutics position peaked at $3.55M in Q1 2021.
148 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.